ACM
SIOX

Atika Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Atika Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,175
Closed -$174K – 82
2017
Q3 		$174K Buy
+3,175
New +$536K 0.05% 78

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Atika Capital Management's SIOX Position: Q3 2017 in Review

Atika Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 8,750 shares — an estimated $1.48M sold.

Atika Capital Management first reported a position in SIOX in Q2 2015 and held it in 7 quarters. The position peaked at $1.89M in Q4 2015. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

  • Atika Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Atika Capital Management sold 8,750 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $1.48M.
  • Atika Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 7 quarters.
  • Atika Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.89M in Q4 2015.
  • 114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on Atika Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.